- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00873483
US Ovulation Inhibition Study in Obese Women
April 6, 2021 updated by: Bayer
Multicenter, Open-Label, Uncontrolled Study to Investigate the Impact of Weight and BMI on Inhibition of Ovulation of a Transdermal Patch Formulation Containing 0.55 mg Ethinylestradiol and 2.1 mg Gestodene in Young Female Volunteers Stratified by BMI Over a Period of 3 Treatment Cycles
Birth Control Patch Study
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
173
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Arizona
-
Tucson, Arizona, United States, 85712
-
-
California
-
San Diego, California, United States, 92108
-
-
Georgia
-
Sandy Springs, Georgia, United States, 30328
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19114
-
-
Texas
-
Houston, Texas, United States, 77054
-
-
Washington
-
Seattle, Washington, United States, 98105
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 35 years (ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Female subject requesting contraception
- Age: 18 - 35 years (inclusive); smokers must not be older than 30 years at the time of informed consent
- Normal cervical smear not requiring further follow-up (a cervical smear has to be taken at screening visit or a normal result has to be documented within the previous 6 months)
- History of regular cyclic menstrual periods
- Willingness to use non-hormonal methods of contraception during the entire study.
Exclusion Criteria:
- Pregnancy or lactation (less than 3 menstrual cycles since delivery, abortion, or lactation before start of treatment)
- Hypersensitivity to any ingredient of the study drug
- Significant skin reaction to transdermal preparations or sensitivity to surgical/medical tape
- Any diseases or conditions that can compromise the function of the body systems and could result in altered absorption, excessive accumulation, impaired metabolism, or altered excretion of the study drug (e.g., known skin disease with suspected alteration of dermal absorption or poor adherence of the patch such as psoriasis)
- Any disease or condition that may worsen under hormonal treatment.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: NON_RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Arm 1
|
0.55 mg ethinyl estradiol & 2.1 mg gestodene, 21 days for 3 cycles
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Determination of Hoogland Scores
Time Frame: Treatment Cycles 2 & 3
|
Treatment Cycles 2 & 3
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Laboratory values for E2, progesterone, FSH and LH
Time Frame: Pretreatment & regularly during Treatment Cycles 1, 2, 3
|
Pretreatment & regularly during Treatment Cycles 1, 2, 3
|
Endometrial thickness
Time Frame: Pretreatment & regularly during Treatment Cycles 1, 2, 3
|
Pretreatment & regularly during Treatment Cycles 1, 2, 3
|
Follicle size
Time Frame: Pretreatment & regularly during Treatment Cycles 1, 2, 3
|
Pretreatment & regularly during Treatment Cycles 1, 2, 3
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
April 30, 2009
Primary Completion (ACTUAL)
March 3, 2010
Study Completion (ACTUAL)
March 3, 2010
Study Registration Dates
First Submitted
March 31, 2009
First Submitted That Met QC Criteria
March 31, 2009
First Posted (ESTIMATE)
April 1, 2009
Study Record Updates
Last Update Posted (ACTUAL)
April 8, 2021
Last Update Submitted That Met QC Criteria
April 6, 2021
Last Verified
April 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Estrogens
- Contraceptive Agents, Hormonal
- Contraceptive Agents
- Reproductive Control Agents
- Contraceptives, Oral, Combined
- Contraceptives, Oral
- Contraceptive Agents, Female
- Contraceptives, Oral, Synthetic
- Contraceptives, Oral, Hormonal
- Progestins
- Ethinyl Estradiol
- Gestodene
- Femovan
Other Study ID Numbers
- 13871
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Contraception
-
Virginia Commonwealth UniversityCompletedPregnancy Related | Contraception | Contraception Behavior | Contraception Use
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedFemale Contraception | Contraception
-
Johnson & Johnson Pharmaceutical Research & Development...Completed
-
Medical University of South CarolinaSociety of Family PlanningCompletedContraception | Contraception BehaviorUnited States
-
Teva Branded Pharmaceutical Products R&D, Inc.CompletedFemale Contraception | ContraceptionUnited States, Israel
-
Johnson & Johnson Pharmaceutical Research & Development...Completed
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedFemale Contraception | Contraception
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedFemale Contraception | Contraception
-
Janssen Pharmaceutica N.V., BelgiumCompleted
-
University of California, San FranciscoAgency for Healthcare Research and Quality (AHRQ); Essential Access HealthNot yet recruitingContraception | Contraception Behavior | Reproductive BehaviorUnited States
Clinical Trials on Ethinylestradiol/Gestodene (BAY86-5016)
-
BayerCompletedContraceptionItaly, Spain, Australia, France, Germany, Argentina, Mexico, Chile
-
BayerParexelCompleted
-
BayerTerminatedContraception | Ovulation InhibitionGermany
-
BayerCompletedContraception | Ovulation InhibitionGermany
-
BayerCompleted
-
BayerCompletedContraceptionUnited States
-
BayerCompletedContraceptionGermany
-
BayerCompleted